Pharmatech Associates, a subsidiary of the United States Pharmacopeia (USP), announced it has appointed the biotech expert Dr. Praveen Tyle to its board of trustees. In nearly 40 years’ experience with small and large biotech organizations, Dr. Tyle has served as executive vice president and chief science officer at USP, and held leadership positions at Lexicon Pharmaceuticals, Osmotica Pharmaceutical, Novartis Consumer Health Group, and Bausch + Lomb.

“As we focus on providing expert consulting services to an array of biotechnology clients, Dr. Tyle’s incomparable experience and valuable market insight will inform the Pharmatech Associates board,” said Emily Kaine, Pharmatech Associates’ board chair. “Dr. Tyle’s commitment and deep understanding of USP also ensure that Pharmatech Associates’ strategic direction contributes to USP’s long term vision of advancing global access to quality medicines.”

“Pharmatech Associates’ capability building services and technical solutions for life sciences companies are a perfect complement to USP’s portfolio of standards and related programs,” said Dr. Tyle. “Backed by USP’s sustained investment and global network, Pharmatech has a promising, ambitious long-term global growth trajectory as it helps drug manufacturers meet international regulatory requirements and their own business objectives.”